Drugs / BA1106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05650242 | Jan 2023 → Dec 2025 | cancer | Shandong Boan Biotechnology Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BA1106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650242 ↗ |
| Modality | Monoclonal antibody | “BA1106 is a human anti-CD25 monoclonal antibody.” NCT05650242 ↗ |
| Route | Intravenous | “BA1106 will be administered by intravenous (IV) infusion.” NCT05650242 ↗ |